Figure 4.

GO treatment circumvents the unfavorable outcomes of high ANXA5 expression in pediatric AML patients. A total of 253 patients were divided into two groups based on the median expression levels of ANXA5. (a, b) Kaplan–Meier curves of OS and EFS in patients with GO treatment (n = 80) and without GO treatment (n = 46) in the high-ANXA5-expression group. (c, d) Kaplan–Meier curves of OS and EFS in patients with GO treatment (n = 78) and without GO treatment (n = 49) in the low-ANXA5-expression group.

AML, acute myeloid leukemia; EFS, event-free survival; GO, gemtuzumab ozogamicin; OS, overall survival.